Ineffective, Inferior, or Needlessly
Costly New Drugs
The enthusiasm with which these were at first received appears to have been
unwarranted by fuller experience and may be taken as another instance of ill-
judged medical faith in a remedy which is often one of the misfortunes of the pro-
fession. —Editorial on arsenic compounds in the Journal of the American Medical
HAVING CONSIDERED some of the players in disseminating medical advances, it may be helpful to study how they've acted and interacted over specific drugs, devices, operations, and other products. The goal of this section is to describe some illustrative events, first considering new drugs, then surgical procedures, medical devices, and the weight loss industry. For this purpose, probably nothing is better than some good stories. Those recounted here are illustrative, but hardly exhaustive.
for High Blood Pressure*
On a March day in 1995, Dr. Bruce Psaty ascended the podium to present a scientific paper, as he had done many times before.2 At a hotel in San Antonio, he was speaking before the Epidemiology and Prevention Council of the American Heart Association, a small meeting of academic
*This section adapted and reproduced with permission from the BMJ Publishing Group
from Quality and Saftey in Health Care 2002; II: 294–296.
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information: Book title: Hope or Hype: The Obsession with Medical Advances and the High Cost of False Promises. Contributors: Richard A. Deyo - Author, Donald L. Patrick - Author. Publisher: AMACOM. Place of publication: New York. Publication year: 2005. Page number: 169.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.